PANX1 and skin cancer: Because 70% of patients had a previous incidence of skin cancer, we analysed PANX1 expression in tumours which developed at the site of previous skin cancer (local recurrence) or were present at a novel anatomical location (distant recurrence) but found no significant differences in PANX1 levels between sites (Fig. 11F, P = 0.3323).